NeuroEgis is a development stage biopharmaceutical company, which leverages decades of research by its founder and collaborators on mechanisms at the intersection of protein homeostasis (aka, proteostasis) and neuroprotection. NeuroEgis combines world class science and expertise in translational neuroscience. NeuroEgis is pioneering a therapeutic portfolio of proprietary and first-in-class small molecules that aim at preventing, delaying or reversing adverse and pro-death effects of proteinopathies and toxic insults, while promoting neuroprotection against neurodegenerative disease and aging.